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Abstract
Purpose—To investigate SGI-110 as a “chemosensitizer” in ovarian cancer (OC) and to assess 
its effects on tumor suppressor genes (TSG) and chemo-responsiveness associated genes silenced 
by DNA methylation in OC.
Experimental Design—Several OC cell lines were used for in vitro and in vivo platinum 
resensitization studies. Changes in DNA methylation and expression levels of TSG and other 
cancer-related genes in response to SGI-110 were measured by pyrosequencing and RT-PCR.
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Results—We demonstrate in vitro that SGI-110 resensitized a range of platinum-resistant OC 
cells to cisplatin (CDDP) and induced significant demethylation and reexpression of TSG, 
differentiation-associated genes and putative drivers of OC cisplatin resistance. In vivo, SGI-110 
alone or in combination with CDDP was well tolerated and induced anti-tumor effects in OC 
xenografts. Pyrosequencing analyses confirmed that SGI-110 caused both global (LINE1) and 
gene specific hypomethylation in vivo, including TSGs (RASSF1A), proposed drivers of OC 
cisplatin resistance (MLH1 and ZIC1), differentiation-associated genes (HOXA10 and HOXA11), 
and transcription factors (STAT5B). Furthermore, DNA damage induced by CDDP in OC cells 
was increased by SGI-110, as measured by ICP-mass spectrometry analysis of DNA adduct 
formation and repair of cisplatin-induced DNA damage.
Conclusions—These results strongly support further investigation of hypomethylating strategies 
in platinum-resistant OC. Specifically, SGI-110 in combination with conventional and/or targeted 
therapeutics warrants further development in this setting.
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INTRODUCTION
Ovarian cancer (OC) is the deadliest gynecological cancer, causing 14,270 estimated deaths 
and 21,980 new cases in the United States (1). Current treatment for OC includes 
cytoreductive surgery and platinum-based chemotherapy (2). Although most patients 
initially respond to chemotherapy, more than 80% of women develop resistance, with an 
average time to progression ranging from 18 to 24 months (3). Therapeutic options are 
limited for platinum resistant OC and while new targeted agents are currently under clinical 
investigation, a personalized approach has not been easy to implement and has not resulted 
in improved outcomes. The recent genomic description of high grade serous OC revealed 
that even chemotherapy-naïve tumors harbor highly disorganized genomes (4), characterized 
by tens of genetic alterations per tumor. Such molecular chaos is expected to be further 
augmented in the platinum-resistant setting, rendering therapy targeted to single mutations 
highly unlikely to alter outcomes. Indeed, whereas several second-line therapeutic 
approaches have prolonged progression-free survival (PFS), the impact on overall survival 
remains modest (5–7).
Platinum resistance in OC is a complex phenomenon, resulting from alterations in a number 
of key pathways as well as epigenetic anomalies including changes in DNA methylation, 
histone modifications, and nucleosome positioning (8–11). Abnormal DNA methylation 
patterns, such as increased DNA methylation within CG-rich (“CpG islands”) promoter 
regions (often within tumor suppressor genes), is a well-studied transcriptionally repressive 
epigenetic modification (12) occurring frequently in OC. This epigenetic mark can be 
reversed using pharmacological approaches, such as by using DNA methyltransferase 
inhibitors (DNMTIs) (13). We and others previously demonstrated in preclinical studies that 
known DNMTIs decitabine (5-aza-dC) and zebularine resensitize chemoresistant OC cells to 
platinum (14, 15). Recent phase I/II trials showed that low-dose decitabine followed by 
carboplatin resulted in significant clinical and biological activity in women with platinum-
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resistant OC (16–18). Current FDA approved therapeutic DNMTIs are subject to rapid 
degradation by hydrolytic cleavage and deamination by cytidine deaminase and are unstable 
after intravenous infusion limiting their potential as cancer therapeutics (19, 20).
SGI-110, a dinucleotide combining 5-aza-dC and deoxyguanosine (Astex Pharmaceuticals, 
Inc.), has been shown to be less prone to deamination by cytidine deaminase and more stable 
in aqueous solution (21), making it a promising alternative to 5-aza-dC. We conducted a 
preclinical combination study of SGI-110 with cisplatin (CDDP) in OC models and 
demonstrated that pre-treatment with SGI-110 resensitized a range of OC cells to CDDP, 
both in vitro and in vivo. In all, our preclinical studies reveal that SGI-110 is an effective 
DNA hypomethylator in OC and supports its future clinical development in OC and other 
solid tumors. Clinical trials using this combination are ongoing.
MATERIALS AND METHODS
Cell culture and drugs
A2780 OC cells were obtained and authenticated in 2012 from ATCC and cell culture 
reagents were purchased from Invitrogen. A2780-CDDP-resistant cells and CP70-CDDP 
resistant cells were prepared by exposure to incrementally increasing doses of cis-
diamminedichloroplatinum (II) dichloride (CDDP, cisplatin) (Calbiochem) as previously 
described (14). SKOV3, 59M, and OAW28 cells were obtained from the European 
Collection of Cell Cultures (ECACC). 59M and OAW28 cells were maintained in 
Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum (FBS). 
SKOV3 cells were maintained in McCoys 5A medium supplemented with 1.5 Mm 
glutamine and 10% FBS. All other cells were maintained in RPMI 1640 media 
supplemented with 10% FBS and 1% antibiotics, as described previously (14). 5-aza-2'-
deoxycytidine (5-aza-dC) was purchased from Sigma. SGI-110 was provided by Astex 
Pharmaceuticals, Inc. (Dublin, CA).
Platinum resensitization
Treatment with 5-aza-dC (5µM), SGI-110 (0.1, 0.3, 1 and 5µM), or vehicle (DMSO 1:2000) 
was performed for 48hr prior to CDDP treatment (15). MTT and alamar blue (Invitrogen) 
assays were used to determine both IC50 values and growth curves, as described previously 
(15). Details can be found in the online Supplementary Methods.
qRT-PCR
RNA was isolated from cultured OC cells using AllPrep DNA/RNA/Protein Mini kit 
(Qiagen) following manufacturer’s protocol and the quantity and quality determined by 
absorbance (260, 280nm). Total RNA (2 µg) was reverse transcribed with the LightCycler 
480 SYBR Green I Master kit (Roche, Switzerland) and analyzed by qRT-PCR according to 
the manufacturer’s instructions. Primer sequences (Fisher Scientific) can be found in 
Supplementary Table S1. For in vivo qRT-PCR validation assay, the RNA was isolated from 
tumor tissues using TRizol® reagent (Invitrogen, CA) according to the manufacturer’s 
instruction. qRT-PCR was performed using miScript reverse transcription and miScript 
SYBR® Green PCR kits (Qiagen, CA) in a Roche Lightcycler (Roche Applied Science, IN), 
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as described previously (14, 22). mRNA expression level was determined using LightCycler 
software version 3.5 (Roche Applied Science, IN), normalized to EEF1α1b, and using the 
2−ΔΔCT method of relative quantification.
In vivo non-tumor bearing mice experiments and treatment schedule
All animal studies adhered to protocols approved by the Institutional Animal Care and Use 
Committee of Indiana University. Female nude, athymic, BALB/c-nu/nu mice (4–5 weeks 
old) (Harlan) were treated with SGI-110, CDDP, or SGI-110 and CDDP in combination 
according to the treatment schedule provided in Supplementary Figure S1A. SGI-110 was 
administered at either 2mg/kg or 5mg/kg and CDDP was administered at 2mg/kg or 4mg/kg. 
Body weight (BW), eating habits and behavior were monitored biweekly.
In vivo xenograft experiments and treatment schedule
Parental or CDDP-resistant A2780 cells (Sigma) were counted, resuspended in 100µl 1:1 
RPMI 1640/Matrigel (BD Biosciences), and 7×105 cells were injected subcutaneously (s.c.) 
into the right flanks of 4–5 week old female nude athymic mice (BALB/c-nu/nu, Harlan). 
Tumors were allowed to grow to reach a predetermined size (~4–5 mm in diameter) before 
each treatment. Mice bearing similar tumor size (4–5 mm in diameter) were randomly 
assigned to different treatment arms: control, CDDP, SGI-110, or SGI-110 and CDDP 
combination, as summarized in Supplementary Figure S1B. Tumor sizes and BWs were 
measured biweekly. Tumor length (l) and width (w) were measured using digital calipers. 
Tumor volume (v) was calculated using the following equation: v = ½×l×w2. Mice were 
sacrificed if tumors reached a diameter of 2cm or at the end of study. Tumor growth curves 
were analyzed using general linear models. Xenografts were snap frozen for DNA/RNA 
extraction.
DNA extraction and pyrosequencing of blood, tumors and cell lines
DNA was extracted from 100 µl of blood or 25mg tumor tissue using DNeasy Blood & 
Tissue Kit (Qiagen). Sodium bisulfite conversion of genomic DNA, cleanup, and LINE1 and 
specific gene pyrosequencing analysis was performed by EpigenDx Inc. Primers are listed in 
Supplementary Table S2. For cell lines, genomic DNA extraction was performed using the 
QIAamp DNA extraction kit and 100 ng-2 µg of genomic DNA was converted to bisulfite 
DNA using the EpiTect® Plus DNA Bisulfite Kit (Qiagen). Pyrosequencing analysis of 
LINE1 elements, MLH1 and ZIC1 was performed using the PyroMark Q24 in conjunction 
with PyroMark Q24 CpG LINE1, CpG MLH1 and CpG ZIC1 assay kits (Qiagen).
ICP-mass spectrometry analysis
Parental and CDDP-resistant A2780 cells were plated at 2×105 per well in 6-well plates. 
Triplicate wells were treated with either vehicle (DMSO) or 5µM SGI-110 for 48 hours. 
Media was replaced with fresh RPMI containing 10µM CDDP. Cells were incubated for 2hr 
at 37°C and 5% CO2, media was removed and cells washed with phosphate-buffered saline. 
Cells received fresh RPMI without CDDP and were allowed to repair for 0, 2, 4 and 24 
hours. DNA was extracted from cells by lysis in the well and spooling as described by Laird 
et al (23). DNA (30–50 µg) was hydrolyzed overnight in 1% nitric acid at 70°C in 500µL 
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total volume. Samples were then diluted to 1.5mL final volume in 1% nitric acid and 
analyzed by ICP-mass spectrometry as we have previously described (24). Briefly, a 
benchtop series Thermo ICPMS X-series II system with collision cell technology capability 
and PlasmaLab software were used to quantify CDDP concentrations. The argon plasma 
torch purity was at least 99.999% (Praxair Distribution, Inc.). Water was purified with a 
Milli-Q Advantage A10 System (Millipore). Optima nitric acid 67 to 70% (Fisher Scientific) 
was diluted to 2% and used as the solvent matrix while certified standard solutions were 
provided by Inorganic Ventures. ICP-MS calibration was conducted according to the 
manufacturer's specifications, followed by a multipoint curve fitted by linear regression with 
a minimum correlation coefficient (r2) of 0.999. Samples were spiked with Yttrium (Y, 88.9 
Da) and lead (Pb, 207.2 Da) to bracket the CDDP (Pt, 195.1 Da) signal and were used as 
machine controls. Triplicate injections were used to quantify the level of CDDP in each 
individual sample based on a standard curve with elemental CDDP. The standard curve was 
performed with each experimental run and achieved linearity over the range of 
concentrations tested with an r2 of greater than 0.95.
Western blot analysis
Proteins extracted from treated cells were transferred to polyvinylidene difluoride 
membranes and blotted with rabbit anti-β-tubulin (1:4000) (Santa Cruz Biotechnology), anti-
trimethyl-histone-H3 (Lys27) (1:1000) (Millipore), anti-acetyl-histone H4 (Lys16) (1:1000) 
(Millipore), mouse anti-histone H3 (1:1000) (Active Motif, CA), MLH1 (BD Biosciences) 
and actin (Abcam). Goat anti-Rabbit IgG (H+L), peroxidase labeled antibodies (1:4000) and 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) were used for 
detection of H4K16ac and H3K27me3. Infrared-dye-labeled anti-mouse antibodies (Licor 
Bioscience) and the Odyssey infrared imaging system (Licor Biotechnology) were used to 
detect MLH1.
Densitometry used Image J analysis software. Experiments were done in triplicate.
Statistical analysis
Statistical analysis employed the Student’s t-test to compare BW and tumor volume and the 
paired t-test to compare LINE1 and gene-specific methylation levels between mice treated 
with vehicle control, SGI-110, CDDP, or SGI-110 and CDDP. All P-values were corrected 
with the Bonferroni correction method for the number of comparisons. A P-value of 0.05 
was considered statistically significant. All in vitro experiments were reported as means ± 
S.E.M of 3 independent experiments.
RESULTS
SGI-110 modulates sensitivity to CDDP, causes demethylation and gene reexpression in 
vitro
We investigated whether the DNMTIs 5-aza-dC and SGI-110, a dinucleotide antimetabolite 
of 5-aza-dC, modulates the response of OC cells to CDDP. Parental A2780 cells, A2780-
CDDP resistant cells, and CP70-CDDP resistant cells were primed with vehicle, SGI-110, or 
5-aza-dC for 48 hours and then were treated with CDDP. Cell viability was measured by 
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MTT assay. “Priming” with moderate doses (5 µM) of either SGI-110 (Fig. 1A) or 5-aza-dC 
(Supplementary Figure S2) increased the sensitivity of OC cells to CDDP causing a >2-fold 
reduction in the IC50 for CDDP: 28 µM CDDP IC50 for A2780-CDDP resistant cells after 
SGI-110 priming compared to 42 µM CDDP IC50 for parental A2780 cells by CDDP, 
Supplementary Table S3). Interestingly, we observed that SGI-110 increased sensitivity to 
CDDP for both the parental and the resistant A2780 cells. Although among other OC cell 
lines, the parental A2780 is considered to be CDDP “sensitive”, it has a relatively high IC50 
for the drug (Supplementary Table S3).
Previous studies have demonstrated an association between CDDP-resistance of OC cells 
and hypermethylation mediated silencing of several genes including the mismatch repair 
protein MLH1, TSGs, RASSF1A, and the differentiation associated gene HOXA11 (10, 14, 
15), prompting us to measure the effects of SGI-110 on the DNA methylation and 
expression levels of those genes. SGI-110-modulated chemoresensitization of the A2780 
cells was accompanied by demethylation and reexpression of MLH1 gene (Fig. 1B), 
RASSF1A (Fig. 1C) and HOXA11 (Fig. 1D). We also measured the effects of SGI-110 on 
other genes whose hypomethylation correlated with clinical response to decitabine in a 
previous clinical trial (16), noting that SGI-110 induced promoter demethylation of these 
additional genes. Additional results are provided in Supplementary Figure S3.
Next, we evaluated whether a lower dose of SGI-110 (0.3µM) also modulates CDDP-
response in OC cell lines. Cells were pre-treated for 3 days with a low dose of SGI-110 (25), 
prior to exposure to CDDP and cell viability was measured by the alamar blue assay. We 
confirmed that low dose SGI-110 increased sensitivity of A2780 cells to CDDP (9-fold 
sensitization, data not shown) consistent with the observations using higher doses of 
SGI-110 (Fig. 1A). Pre-treatment with SGI-110 increased up to 9-fold and 4-fold CDDP 
sensitivity of OVCAR8 and OAW28 OC cell lines, respectively (Supplementary Figure S4). 
However, the 59M, OVCAR3 and SKOV3 cells were not sensitized to CDDP by exposure 
to low dose SGI-110, suggesting differential cell response to the hypomethylating strategy.
To determine whether the 3 day exposure to low dose SGI-110 induced effective 
hypomethylation in the cell lines analyzed, LINE1 methylation was measured by 
pyrosequencing. Significant demethylation of LINE1 ranged from 17% to 45% (Fig. 1E), 
however no correlation between LINE1 hypomethylating activity of SGI-110 and 
resensitization to CDDP was recorded. As MLH1 reexpression correlated with 
resensitization of A2780 cells to CDDP (Fig. 1B), we next measured the effects of low dose 
SGI-110 on MLH expression levels in other OC cells. We found that MLH1 was not silenced 
in the OVCAR8 or OAW28 cells and treatment with SGI-110 did not modulate MLH1 
expression (Supplementary Fig. S5B, Supplementary Table S4), thus suggesting that the 
SGI-110-regulated mechanisms of CDDP-resistance in these cell lines are distinct from 
those of A2780 cells and not related to MLH1 expression levels.
Epigenetic gene silencing is a potential mechanism of OC CDDP-resistance
Unlike the A2780 models, the contribution of epigenetic silencing of key genes to CDDP- 
resistance of OVCAR8 and OAW28 has not been previously characterized. To investigate 
whether epigenetic mechanisms play a role in CDDP resistance in OVCAR8 and OAW28 
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cells, we analyzed gene expression levels of a panel of candidate drivers of OC CDDP 
resistance (Supplementary Table S5). The candidate genes were previously proposed by us 
(26) and Lum et al. (27), who identified genes that were epigenetically silenced (by 
hypermethylation) in primary samples derived from platinum-resistant OC patients. 
Expression levels of the candidate genes were determined by using real-time PCR, following 
exposure of the cells to SGI-110. Of the 19 candidate genes analyzed, a marked induction of 
DOK2 65-fold at 1 µM SGI–110) and ZIC1 11-fold at 1 µM SGI–110) expression levels 
were observed in response to SGI-110 in the OVCAR8 cell line (Fig. 2A, B). Furthermore, 
an induction of DOK2 41-fold at 1 µM SGI–110) and ZIC1 13-fold at 1 µM SGI–110) was 
also observed in the OAW28 cells, in addition to a modest induction of TWIST1 (3-fold at 1 
µM SGI–110), NR2E1 (7-fold at 1 µM SGI–110) and SOX9 (3-fold at 1 µM SGI–110) 
(Supplementary Figure S6). To determine whether the reexpression of ZIC1 and DOK2 was 
associated with resensitization of OC cells to CDDP, the effect of SGI-110 on ZIC1 and 
DOK2 expression levels was analyzed in the cells not sensizitzed to CDDP by SGI-110 
(59M, OVCAR3 and SKOV3, Supplementary Figure S4). A dose-dependent increase in 
DOK2 expression was observed in all of the cell lines tested, irrespective of response to 
CDDP (Fig. 2A), suggesting that the induction of DOK2 did not contribute to the CDDP- 
resensitization observed in these cell lines. However, SGI-110-dependent induction of ZIC1 
was only observed in the cell lines in which SGI-110 conferred resensitization to CDDP 
(OVCAR8 and OAW28; Fig. 2B, Supplementary Table S6), suggesting that the epigenetic-
silencing of ZIC1 is a potential mechanism of CDDP resistance in these cells.
The methylation levels of ZIC1 in the parental A2780, OVCAR8, OAW28, 59M, OVCAR3 
and SKOV3 cells were next determined by pyrosequencing (Fig. 2C). The highest level of 
ZIC1 methylation was observed in the OVCAR8 (21%), OAW28 (44%), and SKOV3 cells 
(31%). Levels of ZIC1 methylation were much lower in the parental A2780 (4%), 59M (4%) 
and OVCAR3 (4%) cell lines. Interestingly in SKOV3 cells, although ZIC1 was highly 
methylated, SGI-110 treatment did not induce ZIC1 reexpression, indicating that factors 
other than promoter methylation contribute to the repression of ZIC1 in these cells. In 
contrast, SGI-110 reversed the methylation of ZIC1 in a dose-dependent manner in OAW28 
cells (Fig. 2D). Taken together these data suggest that the CDDP resistance observed in 
OVCAR8 and OAW28 cells is at least in part due to hypermethylation of the ZIC1 promoter 
and that the reversal of epigenetic silencing of ZIC1 by SGI-110 can resensitize the cells to 
CDDP. These results point to new potential biomarkers that can explain development of 
platinum resistance in OC and predict response to epigenetic therapies.
SGI-110 tolerability studies in non-tumor bearing mice
To investigate whether SGI-110 alone or in combination with CDDP was tolerable in vivo, 
female nude athymic non-tumor bearing mice were treated with two different schedules 
(QD5 and biweekly) (Supplementary Figure S1A). The QD5 daily schedule was SGI-110 (2 
mg/kg or 5 mg/kg) treatment for five consecutive days alone or followed by CDDP (2 mg/kg 
or 4 mg/kg) on day 8 and was designed to model the regimen used in our previous clinical 
trial testing decitabine (5-aza-dc) as a chemosensitizer (16). The biweekly schedule used 
different doses of SGI-110 (2 mg/kg or 5 mg/kg), CDDP (2 mg/kg or 4 mg/kg), or both 
twice a week for 4 weeks. Animals were observed for three additional weeks post-treatment. 
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In the QD5 schedule, SGI-110 2 mg/kg had no effect on BW compared to SGI-110 5 mg/kg 
(Supplementary Figure S7A). Furthermore, the lower dose SGI-110-CDDP combination was 
well tolerated (Supplementary. Figure S7A, orange line) but initial BW loss was observed 
using the higher dose combinations (Supplementary. Figure S7A, pink and green lines). In 
the biweekly schedule, all SGI-110 and CDDP combinations were well tolerated, based on 
steady increases in BW at each time point examined (Supplementary. Figure S7B). Overall, 
SGI-110 in combination with CDDP at physiologically achievable doses was well tolerated 
in non-tumor bearing mice.
SGI-110 inhibits tumor growth in vivo
Based on the above results in non-tumor bearing mice, low dose SGI-110 (2 mg/kg) was 
used for subsequent OC xenograft experiments. CDDP-resistant A2780 cells were injected 
subcutaneously into the right flanks of 4–5 week old female nude athymic mice, and tumors 
were allowed to form as described. SGI-110 2 mg/kg and SGI-110 2 mg/kg + CDDP (2 
mg/kg or 4 mg/kg), both the QD5 and biweekly schedules, delayed (P<0.05) tumor growth 
(Fig. 3A QD5 treatment schedule and 3B biweekly treatment schedule; tumor growth curves 
for parental A2780 xenografts in Supplementary Figure S8; AUC graphs in Supplementary 
Figure S9). SGI-110 alone or in combination with CDDP was well tolerated overall in tumor 
bearing mice using either treatment schedule (Supplementary Figure S10).
The effect of SGI-110 on LINE1 methylation in PBMCs and TSG methylation and gene 
expression in xenograft tumors was examined in mice bearing parental A2780 or CDDP-
resistant A2780 xenografts. PBMC LINE1 demethylation was observed in SGI-110-treated 
mice but not in control or single agent CDDP-treated mice (Fig. 4, QD5 and biweekly 
treatment schedules). Interestingly, SGI-110 hypomethylation activity in the biweekly 
regimen was similar to the daily treatment (Fig. 4A–D, QD5 left panels; biweekly right 
panels). In mice harboring parental A2780-derived xenografts and treated with the QD5 
schedule, demethylation and reexpression of AKT1S1, RASSF1A, HOXA10, HOXA11, 
STAT5B, and MLH1 were observed (Fig. 5A). Similarly, using the biweekly schedule, 
SGI-110 treated groups showed significant demethylation and reexpression of all genes 
including BRCA1 (Fig. 5B). Essentially similar demethylation and reexpression results were 
observed for the A2780 CDDP-resistant-derived xenografts in both QD5 and biweekly 
regimens (Fig. 5C, D). CDDP treatment alone had no effect on target gene methylation in 
either biweekly or QD5 treatment of parental or CDDP-resistant A2780 cells (data not 
shown).
SGI-110 increases platinum DNA adducts in vitro
To gain additional insight into a possible mechanism by which SGI-110 resensitized OC 
models to CDDP, we analyzed CDDP adduct formation in parental A2780 cells and A2780-
CDDP resistant cells. Parental A2780 cells and A2780-CDDP resistant cells were pre-
treated with SGI-110 for 48hr and then exposed to CDDP for 2hr followed by a 0, 2, 4, and 
24hr recovery period (described in Methods section). DNA was extracted and CDDP-DNA 
adduct formation was measured by inductively coupled plasma mass spectrometry (ICP-
MS). SGI-110 pretreatment of the parental A2780 cell resulted in an increase in the level of 
CDDP adducts by approximately 40% (0 hour), 20% (2 hours) and 40% (4 hours) after 
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CDDP treatment compared to control, mock treated cells (Fig. 6A; number of CDDP 
adducts provided in Supplementary Figure S11). Despite the higher level of CDDP-DNA 
adducts in the SGI-110 treated cells, the repair rates were largely independent of SGI-110 
treatment. Similar results were obtained for A2780-CDDP resistant cells pretreated with 
SGI-110 compared to control (Fig. 6A). Interestingly, over the 24hr time, pretreatment with 
SGI-110 of both parental A2780 cells and A2780-CDDP resistant cells resulted in an overall 
increase in the level of CDDP-DNA adducts (Fig. 6A). The increased CDDP adduct 
formation may be attributed to the ability of SGI-110 to “relax” chromatin conformation, 
allowing better access of CDDP to DNA (28) with the resulting overall increase in the level 
of CDDP-DNA adducts contributing to the increase efficacy observed in the SGI-110 
treated cells.
SGI-110 treatment alters global levels of active and repressive histone marks
In addition to DNA methylation changes, it was of interest to examine whether the effects of 
SGI-110 on chromatin included altered levels of repressive and active histone transcription 
marks. We examined global levels of H3K27 trimethylation (H3K27me3), a repressive 
histone mark and the H4K16 acetylation (H4K16ac) activating mark, as acetylated histones 
are known to be associated with unmethylated DNA and correlated with a euchromatic state 
(13, 29). Western blot analysis using highly specific antibodies demonstrated that SGI-110 
treatment of parental and resistant A2780 cells decreased levels of H3K27me3 (−l0.4 and 
−0.6321-fold compared to vehicle treatment) and increased H4K16ac levels (2.71 and 1.17-
fold respectively vs. control, Fig. 6B and C). Histone H3 protein levels (control) were 
unchanged after SGI-110 treatment. These results further support the observation that 
increased CDDP adduct formation is associated with a more accessible chromatin 
environment induced by SGI-110.
DISCUSSION
Combining DNMTIs with existing chemotherapeutic agents to overcome acquired drug 
resistance in OC has been proposed by pre-clinical studies from our and other groups (10, 
15, 30–32). Recently a completed phase II trial using DNMTIs as resensitizers to traditional 
chemotherapy in patients with recurrent OC showed clinical and biological activity, 
justifying further examination of other rationally designed epigenetic treatment strategies in 
OC (16, 18). In this study, we demonstrate for the first time that the novel DNMTI SGI-110 
is an effective chemosensitizer in platinum-resistant OC cells in vitro and in vivo and 
demonstrate that SGI-110 induces demethylation of distinct drivers of OC cisplatin 
resistance. We further show that SGI-110 alone, and in combination with CDDP, is well 
tolerated and reduces tumor volumes in OC xenograft models. SGI-110 causes both global 
(LINE1) and gene-specific demethylation, and derepresses key TSGs and differentiation-
associated genes in vivo. In addition, this is the first report that increased CDDP-DNA 
adduct interactions contribute to chemosensitization by a DNMTI.
While epigenetic therapies hold promise for resensitization of chemoresistant tumors (33–
36), DNMTIs are subject to rapid intracellular deamination and aqueous instability (20). 
Compared to other nucleoside analogs currently used for cancer therapy, e.g., 5-azacytidine 
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and decitabine, SGI-110 is resistant to cytidine deaminase and has been shown to have 
antigrowth effects against bladder and colon cancer cells (21, 37). More recently preliminary 
results from a phase I/II in MDS and AML patients (38) showed that delivering SGI-110 as 
a small volume and pharmaceutically stable subcutaneous injection allows longer effective 
half-life and more extended 5-aza-dC exposure window than intravenous infusion. The 
differentiated pharmacokinetic profile offers the potential for improved biological and 
clinical activity and safety over currently available hypomethylating agents. Preliminary 
results from an ongoing phase 2 study of SGI-110 and carboplatin in platinum-resistant, 
recurrent ovarian cancer patients confirmed this improved pharmacokinetic and 
pharmacodynamic profile (39). In a recently completed phase I trial in AML and MDS 
patients, SGI-110 has also been shown to be better tolerated and demonstrate activity in 
those patients who had progressed on decitabine or 5-azacytidine (40). Our preclinical study 
further demonstrates that SGI-110 in combination with a cytotoxic is well tolerated in two 
different treatment regimens and support the concept that SGI-110 provides equivalent or 
perhaps improved drug exposure compared to 5-aza-dC when given 5X daily, as used in the 
aforementioned phase II study using decitabine and carboplatin (16).
Platinum resistance in OC is believed to be multifactorial, resulting from transmembrane 
drug efflux, impairment of DNA mismatch repair, apoptosis, and senescence-promoting 
pathways, and/or gain of base-excision repair, growth-promoting, and metabolic pathways. 
Methylation-induced silencing of various genes and pathways in OC have been reported (8), 
including LINE1 repetitive elements, BRCA1, and MLH1 as well as RASSF1A (41), HSulf-1 
(growth factor signaling) (42), and TUBB3 (class III β-tubulin). Recently discovered, 
candidate TSGs hypermethylated in OC include SPARC (secreted protein acidic and rich in 
cysteine) (43), and ANGPTL2 (angiopoietin-like protein 2) (44). Also, methylation of the 
embryonic developmentally regulated genes HOXA10 and HOXA11 was also found to be 
highly discriminative between normal and malignant ovarian tissues (45). Adding to this list 
and reaffirming other hypomethylated genes, we show that SGI-110 reactivates AKT1S1 
(subunit of mTORC1), IFNAR1 and IL2RG (receptor subunit in Jak/STAT pathway) (46), 
AKT1 (serine/threonine kinase in apoptosis) (47), STAT5B (transcription factor) (48), LRP6 
(cell surface protein in Wnt/beta-catenin signaling cascade), AXIN1 (cytoplasmic G-protein 
signalling regulator) (49), CTNNB1 (β-catenin), and CSNK1D (casein kinase I), and ZIC1 
(zinc finger protein of the cerebellum 1) (26, 27) in OC cells and mouse xenografts. These 
data support the concept that platinum resistance in OC is driven in part by hypermethylated 
TSGs.
The multifactorial nature of OC CDDP resistance presents a clinical problem. In this study, 
we use a range of OC cell lines to demonstrate that SGI-110 is able to reverse distinct 
mechanisms of CDDP resistance. We have previously demonstrated that DNA methylation 
and gene silencing of a sonic hedgehog (Hh) pathway member and putative TSG ZIC1, in 
OC tumors results in loss of negative regulation of the Hh pathway and contribute to OC 
progression (26). Here we demonstrate that ZIC1 hypermethylation is associated with CDDP 
resistance in the OAW28 and OVAR8 cell lines. We postulate that SGI-110-induced 
demethylation and reexpression of ZIC1 (Fig. 2B, D) confers negative regulation of the Hh 
signaling pathway and inhibition of OC cell proliferation. We further show that SGI-110 is 
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an effective pharmacological approach for reversing this “deep silencing” epigenetic mark 
and resensitizing chemoresistant OC cells to platinum.
Consistent with previous studies in bladder cancer cells (37), both 5-aza-dC and SGI-110 
comparably decreased IC50 values in OC cells treated with CDDP (Fig. 1A, Supplementary 
Tables S3, 4). Cisplatin functions by forming platinum-DNA lesions, forcing cells to 
undergo DNA repair or apoptosis. In addition to reactivating TSGs and other cancer-related 
genes and pathways previously silenced by promoter DNA methylation, we hypothesize that 
DNMTIs create a more active (open) chromatin environment, allowing better access of 
CDDP to DNA, and greater adduct formation. Mass spectrometry analysis supports our 
hypothesis that SGI-110 enhances platinum access to chromatin, and the observed changes 
in H3K27me3 and H4K16ac (Fig. 6B, C), repressive and active transcription marks (13, 29), 
respectively further support the concept that SGI-110 induces a “transcriptionally favorable” 
chromatin environment. Furthermore, as acetylated histones are associated with 
unmethylated DNA, nearly absent from methylated DNA regions and correlate with a 
euchromatic state (13), DNMTIs may reestablish chemotherapy drug response cascades by 
creating a more active (open) chromatin environment (5).
In summary, we show that the novel DNMTI SGI-110 sensitizes a range of OC models to 
CDDP. SGI-110 is well tolerated and has global DNA hypomethylating activity, thus 
reactivating numerous genes linked to chemotherapy response and previously associated 
with clinical outcome in OC (16–18). We provide pre-clinical and biological evidence 
supporting further investigation of hypomethylating strategies in platinum-resistant OC in 
general and particularly SGI-110, which compared to current nucleoside analogs is more 
stable, resulting in better drug exposure (37). As therapeutic options for women with 
recurrent and platinum resistant OC are extremely limited (5, 7), SGI-110 in combination 
with conventional and/or targeted therapeutics warrants further development.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational relevance
Platinum-resistant ovarian cancer (OC) is uniformly fatal. Platinum resistance is 
associated with epigenetic anomalies including aberrant DNA methylation, a reversible 
epigenetic mark. We hypothesized that DNA methyltransferase inhibitors (DNMTIs) 
restore OC sensitivity to platinum and our recent phase I/II trial showed that low-dose 5-
aza-dC followed by carboplatin resulted in promising clinical activity in women with 
platinum-resistant OC. However, current DNMTIs are rapidly degraded by hydrolytic 
cleavage, deaminated by cytidine deaminase and unstable during intravenous infusion, 
limiting their potential as cancer therapeutics. SGI-110, a dinucleotide combining 5-aza-
dC and deoxyguanosine (Astex Pharmaceuticals, Inc.), is less prone to deamination and 
more stable. The current preclinical study demonstrates that pre-treatment with SGI-110 
resensitizes OC cells to cisplatin in vitro and in vivo. Mechanistically, the reversal of 
platinum resistance by SGI-110 was due to demethylation and reactivation of numerous 
chemotherapy response-related genes. Our data support clinical evaluation of this 
combination in platinum resistant OC.
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Figure 1. 5-aza-dC and SGI-110 treatment modulates CDDP sensitivity and alters DNA 
methylation and gene expression in vitro
(A). Comparison of cell growth rates of parental A2780 cells, A2780-CDDP resistant cells, 
and CP70 CDDP resistant cells treated with 5µM SGI-110, or vehicle (DMSO 1:2000) for 
48 hours followed by CDDP ranging from 0–50µM CDDP. Mean values ± S.E.M. of 8 
independent experiments in duplicate are reported. All treatments were significantly 
different, at P < 0.05, than vehicle control cells. IC50 values are listed in Supplementary 
Table S3. (B). RT-PCR analysis of MLH1 RNA levels in A2780 cells. Fold change in RNA 
levels were calculated as 2(–ΔΔCT) relative to DMSO-treated cells. (C and D). RASSF1A and 
HOXA11 were significantly demethylated by SGI-110 and the mRNA expression was 
upregulated in A2780-CDDP resistant cells. All changes are significant (P<0.05). (E). Cells 
were treated for 3-consecutive days with 0.1 µM SGI-110, 0.3 µM SGI-110 or DMSO 
(control). LINE1 methylation status was determined by pyrosequencing analysis and 
expressed as % of DMSO-treated cells. Data shown represent mean values ± S.E.M. from 
triplicate experiments.
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Figure 2. SGI-110 induces the expression of potential CDDP-resistance biomarkers in panel of 
OC cell lines
(A, B) Fold-change in mRNA expression of DOK2 and ZIC1 in OC cell lines following 3-
consecutive day treatment with 0.1µM SGI-110, 0.3µM SGI-110, 1µM SGI-110 or vehicle 
(DMSO) quantified by qRT-PCR. Data shown represent mean values ± S.E.M. from 
triplicate samples. (C) Pyrosequencing analysis of basal ZIC1 methylation levels in 
untreated OC cell lines. Data shown represent mean values ± S.E.M. from triplicate samples. 
(D) Pyrosequencing analysis of ZIC1 methylation levels in OAW28 cells, following 3-
consecutive day treatment with SGI-110. Methylation levels expressed as % of DMSO-
treated cells. Data shown represent mean values ± S.E.M. from triplicate experiments.
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Figure 3. SGI-110 and CDDP in the QD5 and biweekly treatment regimens decreases A2780-
CDDP resistant-derived xenograft tumor growth treated with
CDDP-resistant A2780 xenograft tumor volume was compared among single agent and 
combination treatment to vehicle control in two treatment schedules (*: P<0.05, **: P<0.01, 
***: P<0.001). (A). QD5 treatment. (D). Biweekly treatment. Data shown represent mean 
values ± S.E.M. from 5 tumor samples.
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Figure 4. QD5 and biweekly SGI-110 treatments induce changes in LINE1 methylation in 
PBMCs and tumor samples from mice with parental A2780 or CDDP-resistant xenografts
Tumor bearing mice were treated with SGI-110 and CDDP according to biweekly or QD5 
schedule. Blood samples were collected (biweekly: on days 1, 8, 15, 22, and end of study 
(EOS); QD5: on days 1, 8, and EOS). Tumors were collected at (EOS) after the mice were 
sacrificed. DNAs were extracted from PBMCs and tumor and subjected to bisulfite 
conversion and pyrosequencing for LINE1 methylation (*: P<0.05, **: P<0.01, ***: 
P<0.001). (A). PBMC LINE1. Left panel- parental A2780 xenograft mice with QD5 
Fang et al. Page 19
Clin Cancer Res. Author manuscript; available in PMC 2015 December 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
regimen, right panel- parental A2780 xenograft mice with biweekly regimen. (B). Tumor 
LINE1. Left panel- parental A2780 xenograft mice with QD5 regimen, right panel- parental 
A2780 xenograft mice with biweekly regimen. (C). PBMC LINE1. Left panel- A2780-
CDDP resistant xenograft mice with QD5 regimen, right panel- A2780-CDDP resistant 
xenograft mice with biweekly regimen. (D). Tumor LINE1. Left panel- A2780-CDDP 
resistant xenograft mice with QD5 regimen, right panel- A2780-CDDP resistant xenograft 
mice with biweekly regimen. Data shown represent mean values ± S.E.M. from 5 xenograft 
samples.
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Figure 5. qRT-PCR and pyrosequencing analysis of specific genes in QD5 and biweekly schedule 
mice with parental and CDDP-resistant A2780 xenografts
Selected specific genes showed significantly demethylated and upregulated from A2780 
xenografts in the 2 treatment schedules. (A). Parental A2780 xenografts from mice treated 
with QD5 schedule. (B). Parental A2780 xenografts from mice treated with biweekly 
schedule. (C). A2780-CDDP resistant xenografts from mice treated with QD5 schedule. (D). 
A2780-CDDP resistant xenografts from mice treated with biweekly schedule. Data shown 
represent mean values ± S.E.M. from 5 xenograft samples.
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Figure 6. SGI-110 increased CDDP DNA adducts and alters epigenetic marks in vitro
Parental A2780 and A2780 CDDP-resistant cells were treated in triplicate with either no 
SGI-110 or 5µM SGI-110 in fresh RPMI and grown for 48 hours. Media was removed and 
replaced with fresh RPMI containing 10µM CDDP for 2hr and were allowed to repair for 0, 
2, 4 and 24 hours DNA was extracted from cells analyzed by ICP-mass spectrometry. (A). 
SGI-110 increased CDDP DNA adducts in vitro. (B and C). Western blot and quantification 
of protein from parental A2780 and A2780 CDDP-resistant cells treated with 5µM SGI-110 
for 48hr and blotted with rabbit anti-β-tubulin, mouse anti-histone H3, and anti-acetyl-
Fang et al. Page 22
Clin Cancer Res. Author manuscript; available in PMC 2015 December 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
histone H4 (B), or anti-trimethyl-histone-H3 (C). Data shown represent mean values ± 
S.E.M. from triplicate experiments.
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